Breyanzi revenues were $344 million, growing 122% globally, with U.S. sales more than doubling to $255 million.
Camzyos global sales were $260 million, growing 86%, driven by new patient starts and inventory build.
Cash, cash equivalents, and marketable securities totaled roughly $13.9 billion as of June 30.
Cash flow from operations was about $3.9 billion in the second quarter.
Cobenfy sales were $35 million in the quarter and $62 million year-to-date, tracking as expected with steady weekly prescription growth.
Diluted earnings per share was $1.46, including a $1.5 billion or $0.57 per share charge related to the BioNTech partnership.
Eliquis global sales were $3.7 billion, growing 6%, with U.S. sales up 4% and ex-U.S. sales up 12%.
Gross margin was approximately 73%, primarily due to product mix.
Growth portfolio sales increased approximately 17% year-over-year, driven primarily by demand for the IO portfolio, Breyanzi, Reblozyl, and Camzyos.
Opdivo global sales were approximately $2.6 billion, up 7%, with strong U.S. launch in MSI-high colorectal cancer and growth in first-line non-small cell lung cancer.
Operating expenses were approximately $260 million lower than the prior year, reflecting strategic productivity initiatives.
Qvantig sales were approximately $30 million, with a successful U.S. launch and permanent J-Code received on July 1.
Reblozyl global sales were $568 million in the quarter, with 30% growth in the U.S. and 46% growth outside the U.S.
Sotyktu sales grew 29% globally, with 5% growth in the U.S. despite higher rebates.
The company is on track to pay down $10 billion of debt by the first half of 2026.
Total company revenues were approximately $12.3 billion in Q2 2025, reflecting strong demand across the business.
Expenses aligned with expectations as the company fully transitioned into commercialization mode.
Liquidia closed Q2 2025 with $173 million in cash and cash equivalents, supporting ongoing commercialization and pipeline investments.
Q2 revenue totaled $8.8 million, including $6.5 million from YUTREPIA product sales and $2.3 million from treprostinil injection promotion services with Sandoz.
R&D expenses are expected to increase in the second half of 2025 due to ongoing label studies and initiation of the pivotal L-606 study.
SG&A expenses, excluding noncash and variable treprostinil costs, are expected to remain flat in upcoming quarters.
Dafinchi